Retinopathy of prematurity

被引:4
作者
Promelle, V. [1 ,2 ]
Milazzo, S. [1 ,2 ]
机构
[1] Ctr Hosp Univ Amiens Picardie, Ctr EVICR Net APOCHU 86, Serv Ophtalmol, F-80054 Amiens 1, France
[2] Univ Picardie Jules Verne, Chemin Thil, F-80025 Amiens, France
来源
JOURNAL FRANCAIS D OPHTALMOLOGIE | 2017年 / 40卷 / 05期
关键词
Retinopathy of prematurity; Screening; Angiogenesis; Threshold disease; Pre-threshold disease; Laser peripheral retinal ablation; VEGF inhibitors; EFFICACY; EYES; BEVACIZUMAB; INFANTS; RISK;
D O I
10.1016/j.jfo.2016.12.013
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Retinopathy of prematurity is a retinal vasoproliferative disease affecting extremely preterm infants exposed to high concentrations of oxygen therapy. Infants born before 32 post-menstrual weeks or with a birth weight of less than 1500 g should systematically have a dilated fundus examination. The time of screening and schedule for follow-up are guided by the various risk factors. This disease results from immaturity of the peripheral retinal vessels at the time of premature birth. The classification of ROP depends on the anteroposterior extent of involvement (from center to periphery: zone I, II and III), its extension in 30 degrees. sectors (clock hours) and its stage (stage 1 to 5). "Plus'' disease is defined as dilation and tortuosity of the retinal blood vessels in the posterior pole of the eye and represents a major risk factor for rapid unfavorable progression. A majority of patients will spontaneously recover, but patients with a high risk of progression will require treatment to prevent retinal detachment and blindness. The indications for treatment are threshold disease and type 1 pre-threshold disease. The current treatment of choice is peripheral retinal ablation with transpupillary laser, but ab externo cryotherapy may be used instead. Intravitreal injection of vascular endothelial growth factor inhibitors may be an attractive therapeutic option and is currently under investigation. After laser treatment, unfavorable outcomes occur in only 9 to 14% of eyes, but at the price of peripheral retinal destruction. For all patients, whether treated or not, a regular fundus examination should be insured until complete retinal vascularization has occurred. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:430 / 437
页数:8
相关论文
共 28 条
[1]  
Agence Nationale de securite du medicament et des produits de sante, UT COLL MYDR PED OBT
[2]  
Barjol A, 2015, RECOMMANDATIONS FRAN
[3]  
Basmak H, 2010, EUR J OPHTHALMOL, V20, P752
[4]   Retinopathy of prematurity. Results of fundus examination performed in 94 preterm infants [J].
Beby, F ;
Burillon, C ;
Putet, G ;
Denis, P .
JOURNAL FRANCAIS D OPHTALMOLOGIE, 2004, 27 (04) :337-344
[5]  
Commission de la transparence de la Haute Autorite de sante, 2011, ATROPINE ALCON 0 3 C
[6]  
Commission de la transparence de la Haute Autorite de sante, 2015, NEOSYNEPHRINE 2 5 FA
[7]   Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network [J].
Darlow, BA ;
Hutchinson, JL ;
Henderson-Smart, DJ ;
Donoghue, DA ;
Simpson, JM ;
Evans, NJ .
PEDIATRICS, 2005, 115 (04) :990-996
[8]   Screening Examination of Premature Infants for Retinopathy of Prematurity [J].
Fierson, Walter M. ;
Saunders, Richard A. ;
Good, William ;
Palmer, Earl A. ;
Phelps, Dale ;
Reynolds, James ;
Chiang, Michael F. ;
Ruben, James B. ;
Granet, David B. ;
Blocker, Richard J. ;
Bradford, Geoffrey E. ;
Karr, Daniel J. ;
Lueder, Gregg T. ;
Lehman, Sharon S. ;
Siatkowski, R. Michael .
PEDIATRICS, 2013, 131 (01) :189-195
[9]   Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control [J].
Gilbert, Clare .
EARLY HUMAN DEVELOPMENT, 2008, 84 (02) :77-82
[10]   The international classification of retinopathy of prematurity revisited [J].
Gole, GA ;
Ells, AL ;
Katz, X ;
Holmstrom, G ;
Fielder, AR ;
Capone, A ;
Flynn, JT ;
Good, WG ;
Holmes, JM ;
McNamara, JA ;
Palmer, EA ;
Quinn, GE ;
Shapiro, MJ ;
Trese, MGJ ;
Wallace, DK .
ARCHIVES OF OPHTHALMOLOGY, 2005, 123 (07) :991-999